	US 11,814,354 B2
	Solid forms
He Hongyan, Shanghai (CN); Jiang Siyi, Shanghai (CN); Urs Schwitter, Little Falls, NJ (US); Pascal Jean Claude Dott, Littlefalls, NJ (US); Ralph Diodone, Little Falls, NJ (US); Nicole Wyttenbach, Little Falls, NJ (US); and Olaf Grassmann, Little Falls, NJ (US)
Assigned to River 3 Renal Corp., New York, NY (US)
Filed by River 3 Renal Corp., New York, NY (US); and Hoffmann-La Roche Inc., Little Falls, NJ (US)
Filed on Sep. 7, 2022, as Appl. No. 17/939,203.
Claims priority of provisional application 63/243,813, filed on Sep. 14, 2021.
Claims priority of application No. 202111049581.4 (CN), filed on Sep. 8, 2021.
Prior Publication US 2023/0242485 A1, Aug. 3, 2023
Int. Cl. C07D 213/64 (2006.01)

CPC C07D 213/64 (2013.01) [C07B 2200/13 (2013.01)]

17 Claims

1. A crystalline form of 5-(3,4-dichlorophenyl)-N-((1R,2R)-2-hydroxycyclohexyl)-6-(2,2,2-trifluoroethoxy)nicotinamide, anhydrate (Form E), characterized by a powder X-ray diffraction pattern having characteristic peaks in degrees 2θ at about 10.3, 15.9, and 20.6.